FeesSafety
Pluang+

AbbVie offers a growing 2.4% dividend but trades at a high valuation, worth watching for long-term investors.

Company Fundamentals
21 Nov 2026, 20:10 WIB
Selena Maranjian
View Source
Bullish
AbbVie offers a growing 2.4% dividend but trades at a high valuation, worth watching for long-term investors.

AbbVie currently yields a solid 2.4% dividend, with a history of 53 consecutive years of dividend increases, making it a Dividend King. The quarterly payout has steadily grown from $0.57 in 2016 to $1.82 now. Despite strong recent earnings and growth in key drugs, the stock trades at a higher valuation than its five-year average, suggesting investors might wait for a better entry point or start a small position for the long term. AbbVie remains a compelling option for healthcare investors focused on income and growth over many years.

As of Nov 21, 2026 21:02 WIB, AbbVie (ABBV) trades on Pluang at USD 286.20 with a 1-day gain of 0.94%. The stock's dividend yield is currently 2.45%, closely matching the article's noted 2.4%. Despite strong investor selling interest at 98% of order activity, AbbVie remains a significant healthcare name with a market cap of $505.89 billion on Pluang.

More News (ABBV)

AbbVie offers a solid 2.4% dividend yield with consistent growth, but its valuation is currently high.

AbbVie offers a solid 2.4% dividend yield with consistent growth, but its valuation is currently high.

Pharmaceutical company AbbVie currently has a 2.4% dividend yield, with dividends growing steadily over the years, making it a Dividend King with 53 consecutive years of increases. Despite a strong recent stock price increase of 28% year-to-date and ...

Company Fundamentals
Bullish
5 hours ago
AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.

AbbVie and Eli Lilly are key pharmaceutical players with distinct strengths for 2027. AbbVie focuses on immunology and aesthetics with solid cash flow and a lower valuation, making it a value pick. Eli Lilly dominates metabolic health with rapid reve...

Market News
Bullish
1 day ago
Invest $100K in 4 dividend stocks to earn $4,375 yearly passive income with steady payouts.

Invest $100K in 4 dividend stocks to earn $4,375 yearly passive income with steady payouts.

Investing $100,000 evenly across four blue-chip dividend stocks—AbbVie, Chevron, Realty Income, and Verizon—can generate about $4,375 in annual passive income. These companies offer yields ranging from 2.48% to 6.16%, with Realty Income paying monthl...

Company Fundamentals
Bullish
3 days ago
4 dividend stocks offer faster payout growth than SCHD ETF for retirees seeking income growth.

4 dividend stocks offer faster payout growth than SCHD ETF for retirees seeking income growth.

The Schwab U.S. Dividend Equity ETF (SCHD) is popular among retirees for steady income but has shown minimal dividend growth recently. Four blue-chip stocks—AbbVie, Johnson & Johnson, Procter & Gamble, and Coca-Cola—are highlighted as better alternat...

Market News
Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App